Salivary duct carcinoma is a high-grade adenocarcinoma that resembles breast ductal carcinoma. It is believed to be derived from intra-and interlobular excretory ducts. Salivary duct carcinoma may arise de novo or as a relatively common malignant component of a carcinoma ex pleomorphic adenoma. It accounts for about 9% of all malignant salivary gland tumors. Although there is a wide age range at presentation, most patients present in the seventh decade of life; men are affected much more frequently than women (4:1).
The vast majority of cases arise in the parotid gland, where they usually manifest as a rapidly growing mass, often with ulceration and facial nerve palsy. Patients with carcinoma ex pleomorphic adenoma may have a history of a long-standing mass with recent enlargement.
Because lymph node metastasis occurs frequently, aggressive multimodality therapy is required; surgery, radiotherapy, and chemotherapy yield the best out- comes. Administration of trastuzumab may be useful in patients with HER-2/neu-positive tumors. The overall prognosis is poor, as rates of recurrence and metastasis are high and 5-year survival is less than 35%.
The average size of these tumors is 3.5 cm. They are predominantly solid with a generally white, gray, or tan cut surface. Cysts, necrosis, and hemorrhage are frequently seen. Invasion is easily identified (figure 1), although it is more common in de novo tumors than in those that arise from carcinoma ex pleomorphic adenoma. There is significant lymph-vascular and perineural invasion (figure 2), which is often associated with positive resection margins. Stromal fibrosis or infarction and inflammatory infiltration is often conspicuous.
Salivary duct carcinomas are similar to both intraductal and infiltrating ductal carcinomas of the breast. They feature large ducts with solid, papillary, 
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The neoplastic cells are reactive with several keratins, including CK5/6, EMA, and CEA, while demonstrating a strong and diffuse membranous HER-2/ neu immunoreaction and strong nuclear positivity for androgen receptor (figure 3). In general, salivary duct carcinoma must be distinguished from metastatic breast carcinoma, poorly differentiated squamous cell carcinoma, cystadenocarcinoma, and oncocytic carcinoma. 
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malignancy usually resides in the anterior maxilla and sinonasal structures.' The median age at diagnosis is 52 years.' The neoplasm characteristically presents with painless swelling that sometimes becomes painful in later stages. Findings on CT include a hypodense soft-tissue mass with scattered chondroid matrix calcifications. These calcifications characteristically appear in a ringlike or arc-whorl pattern; amorphous or absent calcifications are suggestive of a high-grade tumor. MRI may further define the extent of soft-tissue involvement. Characteristic MRI findings are an increased T2 signal and heterogeneous enhancement on Tl-weighted imaging with contrast. 5 Reported 5-year survival rates range between 32 and 87.5%.2 The most effective treatment modality is wide surgical resection with clear margins, as residual disease is a primary factor in recurrence. Although adjuvant radiotherapy has not been shown to have a significant effect on survival, it is used in cases of incomplete resection, high-grade lesions, and disseminated disease.'
In our case, the patient was found to have a chondrosarcoma of the left maxilla with extension into the infratemporal fossa. Our case was presented to the multidisciplinary planning conference, and recommendations were made for maxillectomy and resection of the infratemporal fossa followed by radiotherapy.
